NIHSS - What does NIHSS stand for? Acronyms and abbreviations by the Free Online Dictionary.

Acronym

Definition

NIHSS

National Institute of Health Stroke Scale

? References in periodicals archive
Analysis of mRS responders was a prespecified secondary analysis, with 'responders' defined as mRS at 3 months = 0 if NIHSS score at baseline was 4-7, mRS at 3 months = 0-1 if NIHSS score at baseline was 8-14, and mRS at 3 months = 0, 1, or 2 if NIHSS score at baseline was 15-22. New AbESTT Data Show Significant Benefits of ReoPro-R- in Ischaemic ... by Business Wire Analysis of mRS responders was a prespecified secondary analysis, with 'responders' defined as mRS at 3 months = 0 if NIHSS score at baseline was 4-7, mRS at 3 months = 0-1 if NIHSS score at baseline was 8-14, and mRS at 3 months = 0, 1, or 2 if NIHSS score at baseline was 15-22. New AbESTT Data Show Significant Benefits of Reopro-R- in Ischaemic ... by Business Wire The pre-specified, primary outcome measurement of the trial was the comparison of the percentages of patients treated with citicoline or placebo who achieved at least a 7-point improvement on NIHSS (National Institutes of Health Stroke Scale) scores from enrollment through the combined 12-week treatment and follow-up period. Citicoline Stroke Trial Does Not Achieve Primary Clinical Endpoint by Business Wire More results

? References in periodicals archive

Analysis of mRS responders was a prespecified secondary analysis, with 'responders' defined as mRS at 3 months = 0 if NIHSS score at baseline was 4-7, mRS at 3 months = 0-1 if NIHSS score at baseline was 8-14, and mRS at 3 months = 0, 1, or 2 if NIHSS score at baseline was 15-22.

New AbESTT Data Show Significant Benefits of ReoPro-R- in Ischaemic ... by Business Wire

New AbESTT Data Show Significant Benefits of Reopro-R- in Ischaemic ... by Business Wire

The pre-specified, primary outcome measurement of the trial was the comparison of the percentages of patients treated with citicoline or placebo who achieved at least a 7-point improvement on NIHSS (National Institutes of Health Stroke Scale) scores from enrollment through the combined 12-week treatment and follow-up period.

Citicoline Stroke Trial Does Not Achieve Primary Clinical Endpoint by Business Wire

More results